Stroke Drug Development Targeting Ferroptosis

Ferroptosis can interact with the pathological processes of stroke through different pathways, including iron, lipid peroxidation, and amino acid metabolism processes. Studies have confirmed that inhibitors targeted ferroptosis have potential therapeutic effects in the treatment of stroke. Therefore, Ace Neuroscience offers a comprehensive service from the identification of ferroptosis targets to the pharmacological evaluation of ferroptosis inhibitors in stroke to promote the research of stroke drugs targeting ferroptosis.

Stroke Drug Development Targeting Ferroptosis

Target Identification & Characterization

Current studies have shown that targeting the lipid peroxidation process, ACSL4, system Xc-, GPX4, and other targets can effectively block ferroptosis in stroke, but the number of targets is still limited and there is still a need to find more targets to target ferroptosis in stroke. Therefore, Ace Neuroscience has established a specific platform for the identification and characterization of targets targeting the ferroptosis process in stroke.

  • We perform high-throughput screening of candidate targets for ferroptosis-associated pathways in stroke through genomics, proteomics, and metabolomics platforms.
  • We establish in vitro and in vivo modeling of target expression aberrations through drug administration and genetic manipulation to assess the role of candidate targets.
  • We investigate the mechanism of action of candidate targets through gene expression profiling, signaling pathway studies, and bioinformatics analysis.

High Throughput Screening of Ferroptosis Inhibitors

After screening for potential targets of ferroptosis in stroke, we perform high-throughput screening of ferroptosis inhibitors against the targets to identify drugs with potential therapeutic activity in stroke. Thus, Ace Neuroscience provides a platform for high-throughput screening against ferroptosis inhibitors and provides experimental models of ferroptosis to validate the effects of candidate inhibitors.

  • Based on our small molecule library, including ultra-large compound library, natural product library, and fragment library, we have established different high throughput screening platforms for targets and known ferroptosis inhibitors.
  • We chemically modify potential ferroptosis inhibitors to make them safer and more stable.
  • We provide in vitro and in vivo models related to ferroptosis to validate the effect and mechanism of action of the inhibitor.

Preclinical Evaluation of Drug Candidates for the Treatment of Stroke

We have demonstrated the inhibition of ferroptosis by candidate ferroptosis inhibitors. Immediately after, we offer various pharmacological activity assessment services to test the therapeutic efficacy of candidate ferroptosis inhibitors against stroke.

  • We provide different in vitro and in vivo stroke models to validate the therapeutic effect of ferroptosis inhibitors on stroke and to further explore the mechanism of action of ferroptosis.
  • We investigate the effects of candidate inhibitors on ferroptosis-related signaling pathways by molecular co-expression correlation, molecular interaction means, molecular localization, activity, conformation, and other assays.

If you would like to learn more about our services, please feel free to contact us.

  1. Fang, X. L., et al., Ferroptosis-a novel mechanism with multifaceted actions on stroke. Front Neurol, 2022. 13: p. 881809.
  2. Bu, Z. Q., et al., Emerging role of ferroptosis in the pathogenesis of ischemic stroke: A new therapeutic target? ASN Neuro, 2021. 13: p. 17590914211037505.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket